X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Pfizer Binds With $22B Paxlovid Plan Amidst Slow Demand

Content Team by Content Team
4th May 2022
in News
Pfizer’s new partnership focuses on digitising clinical trials

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Pfizer officials stated on an earnings call that while Paxlovid’s first-quarter sales may seem to be low, there will be plenty more revenues in the next three months. Paxlovid, Big Pharma’s COVID-19 oral antiviral, may soon benefit from agreements in China and Europe, as per the company.

For the very first three months of 2022, Pfizer earned $25.7 billion in sales. When the pandemic haul from BioNTech-partnered vaccine Comirnaty plus oral antiviral Paxlovid is subtracted, operational revenue climbed by 2%, according to the company’s financial report. Revenue was a whopping 82% using COVID assets.

Pfizer has maintained its full-year revenue target of $98 billion to $102 billion. As per the business, Comirnaty is expected to provide $32 billion, whereas Paxlovid will contribute around $22 billion.

According to a press release from Comirnaty, the firm produced $13.2 billion in direct sales, which was fueled in part by global penetration of paediatric and booster dosages. On the other hand, Paxlovid made $1.5 billion in revenue during the quarter. In December 2021, the medicine was released in the United States.

Although there have been reports of waning demand for the tablet, Cantor Fitzgerald analysts stated in a letter to investors earlier this week that Paxlovid’s peak sales growth rate remained substantially under-appreciated. While many details were kept under wraps during Pfizer’s quarterly results call, the company did imply that the drug could benefit from certain near-term sales prospects across Europe and China. Furthermore, the drug will eventually be a commercial possibility in the United States.

Pfizer has bilateral deals that have been secured or are next to be secured in several countries, as per Angela Hwang, Pfizer’s group biopharmaceuticals president. At around the same time, the company is pursuing an EU-level deal, according to Hwang, who hinted that more information might be forthcoming soon.

Pfizer is also working with the local distributor, Meheco, in China to assure accessibility to the medicine, though it is unable to reveal financial terms or transaction volumes, as per Hwang. When it comes to transitioning Paxlovid to a regular commercial model in the United States, Pfizer’s chief scientific officer, Mikael Dolsten, M.D., Ph.D., stated that the firm aims to file its proposal for full clearance quite soon, most likely in the first part of the year.

Dolsten said that final approval will go a long way toward improving education and access in Paxlovid. Pfizer produced more than 6 million Paxlovid treatment courses by the end of March, all of which were shipped, according to CEO Albert Bourla, Ph.D. Since the international financial calendar quarter ends in February and the vast bulk of Pfizer’s Paxlovid courses are manufactured in March, only a tiny part of these consignments were mentioned in the first quarter sales, the CEO explained, adding that the company had dispatched approximately 8 million Paxlovid courses as of May 3rd.

Pfizer is on target to deliver 24 million courses in the second quarter, bringing the total for the first half of the year to 30 million, according to Bourla. The United States has stepped in with the intention of buying 20 million Paxlovid courses and also assisting in the production and distribution of the pills.

Previous Post

Teva And Lupin Reach Settlement In AUSTEDO Patent Dispute

Next Post

Newer Omicron Types Initiate Their Own Coronavirus Waves

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Newer Omicron Types Initiate Their Own Coronavirus Waves

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In